Jazz was founded on – and continues to foster – a culture of collaboration, innovation and inclusion that values integrity, passion and the pursuit of excellence that is grounded in a deep commitment to patients.
As an exciting progression of this legacy, we recently announced a new collaboration with Stand Up To Cancer (SU2C) to accelerate cancer research in areas of significant need and to also discover how we can improve access to cancer therapies for people from underserved communities. And while these objectives are undoubtedly bold, I am confident we will achieve significant results owing to the proven ability of Stand Up To Cancer to rapidly activate its expansive network of leading researchers and scientists through its Catalyst program.
By helping to bridge the gaps that can sometimes occur between academics and companies when conducting clinical translational research, the SU2C Catalyst program embodies the type of multisectoral partnerships that we at Jazz know are integral to addressing some of the largest hurdles in healthcare. As such, we are eager to not only offer access to specific molecules in our oncology pipeline but are also grateful that our own industry-leading researchers will have the opportunity to collaborate with their peers from academia and potentially discover new innovations that may impact the lives of people living with cancer.
The importance of the collaboration and necessity for rapid progress cannot be overstated, as a large focus of this collaboration includes research into new treatment options for children living with rare and hard-to-treat solid tumors – building on our commitment to pediatric oncology. Additionally, researchers will be exploring how another one of our molecules may be used to treat RAF- and RAS-mutated solid cancers, which make up about one-third of all cancers.
We are also working with Stand Up To Cancer to better understand the attitudes and perspectives of healthcare providers, patients and their families – particularly from underserved communities – when it comes to their experiences with SCLC clinical trials. This area of research is one that I am particularly proud to have the opportunity to support. One of our main priorities at Jazz is to address disparities in health care, and this research will drive actionable insights on how we can increase access to cancer trials – and their potentially lifesaving therapies – for communities that have been historically underrepresented.
Strategic collaborations like this present meaningful opportunities to address areas of significant need, including difficult-to-treat cancers where there are limited therapeutic options available. We recognize that our medicines have the potential to help only as many people as they can reach. Jazz Pharmaceuticals is proud to collaborate with Stand Up To Cancer and support the Catalyst program to expedite the development of new, better treatments for patients diagnosed with difficult-to-treat cancers, while mining insights on how we can provide equal access to all of our advancements.
